We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

General or Regional Anesthesia for Hip Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01733472
Recruitment Status : Completed
First Posted : November 27, 2012
Last Update Posted : November 6, 2014
Information provided by (Responsible Party):
Andreas Harsten, Region Skane

Brief Summary:
The purpose of this study is to determine whether general anaesthesia or regional anaesthesia is best for patients undergoing Total Hip Arthroplasty.

Condition or disease Intervention/treatment
Osteoarthritis Drug: GA-arm, remifentanil Drug: placebo

Detailed Description:

A randomized controlled trial (RCT) with a follow up time of 48 hrs. Patients scheduled for primary Total Hip Arthroplasty. A total of 120 patients randomly assigned to one of the two alternatives (general anaesthesia (GA) or regional anaesthesia (RA)).

General anaesthesia compared to intrathecal anaesthesia will give shorter length of hospital stay (LOS) for patients undergoing total hip arthroplasty (THA).

Primary endpoint:


Secondary endpoints:

Postoperative pain? Postoperative orthostatic function (dizziness) Time until the patient meets the discharge criteria from PACU How many patients will need at least one urinary bladder catheterisation

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: General Versus Intrathecal Anaesthesia for Patients Undergoing Elective Total Hip Arthroplasty
Study Start Date : January 2013
Primary Completion Date : February 2014
Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anesthesia
U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: RA-arm
RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
Drug: placebo
Experimental: GA-arm, remifentanil
GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
Drug: GA-arm, remifentanil
Remifentanil and propofol will be delivered intravenously via TCI pumps according to the "Marsh" and "Minto" algorithm
Other Name: GA: TCI consisting of remifentanil an dpropofol

Primary Outcome Measures :
  1. Length of hospital stay [ Time Frame: 4 days after surgery ]
    Time from the end of surgery until the patients meets the discharge criteria will be evaluated

Secondary Outcome Measures :
  1. Post operative pain [ Time Frame: from end of surgey until 48 hrs later ]
    Pain will be monitored using a Visual Analogue Scale. Pain will be monitored with the patient in four different positions

Other Outcome Measures:
  1. Time until the patient meets the discharge criteria from PACU [ Time Frame: 12 hrs ]
    Time until the patient meets the discharge criteria from PACU will be monitored every 15 min from teh time the patient arrives to PACU until he/she meets the discharge criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   46 Years to 84 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: patients with osteoarthritis scheduled for surgery

  • patients that will require THA
  • patients over 45 yrs and under 85 yrs.
  • patients that understand the given information and are willing to participate in this study
  • patients who have signed the informed consent document.
  • patients belonging to ASA class I-III.

Exclusion Criteria:

  • prior surgery to the same hip
  • patients with a history of stroke, neurological or psychiatric disease that potentially could affect the perception of pain
  • obesity (BMI > 35)
  • active or suspected infection
  • patients taking opioids or steroids
  • patients suffering from rheumatoid arthritis or an immunological depression
  • patients who are allergic to any of the drugs being used in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01733472

Dept Orthopedic Surgey, Hässleholm Hospital, PO Box 351,
Hässleholm, Sweden, 28125
Sponsors and Collaborators
Region Skane
Principal Investigator: Andreas Harsten, M.D. Region Skane

Responsible Party: Andreas Harsten, M.D., Region Skane
ClinicalTrials.gov Identifier: NCT01733472     History of Changes
Other Study ID Numbers: Hip-CPH-2013
Hässleholm2013 ( Other Identifier: Region Skåne )
First Posted: November 27, 2012    Key Record Dates
Last Update Posted: November 6, 2014
Last Verified: November 2014

Keywords provided by Andreas Harsten, Region Skane:
anaesthetic techniques

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Opioid
Sensory System Agents
Peripheral Nervous System Agents
Hypnotics and Sedatives
Anesthetics, Intravenous
Anesthetics, General